Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Preferred stock receives dividends on an as-converted basis and one vote per share, subject to limitations.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Preferred stock receives dividends on an as-converted basis and one vote per share, subject to limitations
- Conversion requires stockholder approval, with each preferred share convertible into five common shares
- Holder conversion capped at beneficial ownership levels between 0% and 19.99%
- Majority preferred-holder consent required for adverse amendments, additional preferred issuance, or qualifying mergers before approval
- No liquidation preference, limiting downside protection relative to senior preferred securities
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Cullgen acquisition closed May 4, 2026 through merger, making Cullgen a wholly owned Gyre subsidiary
- All-stock transaction valued Cullgen at approximately $300 million, avoiding disclosed cash funding requirements
- Exchange ratio set at 0.4753, with consideration delivered through common stock or Series B preferred stock
- Each preferred share converts into five common shares, subject to shareholder approval and a 19.99% issuance cap
- In-the-money Cullgen options rolled into Gyre options; out-of-the-money options cancelled without consideration
Item 5.02 · Departure/Election of Directors or Officers
- Thomas Eastling appointed CFO on May 4, 2026, succeeding Ruoyu Chen following her resignation
- CFO transition creates near-term investor focus on financial reporting continuity and integration execution
- Dr. Luo appointed Nominating and Corporate Governance Committee Chair following the Merger
- Dan Weng and Gordon Carmichael joined the Nominating Committee effective at Merger closing
- Cullgen stock plan and in-the-money options assumed and converted into Company Common Stock options, creating potential dilution exposure
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of Designation filed in Delaware for Company preferred stock
- Amendment connected to the referenced merger
- Preferred-stock terms may affect voting, conversion, dividend, liquidation, and merger rights
Item 7.01 · Regulation FD Disclosure
- Forward-looking language centers on stockholder approval of the Conversion Proposal
- Planned resale registration statement tied to the Registration Rights Agreement
- Timing of approval and registration remains uncertain
- Investors should monitor dilution and potential resale activity following conversion
Item EX-99.1 · Exhibit EX-99.1
- Cullgen acquisition closed in an all-stock transaction valued at approximately $300 million
- Cullgen became wholly owned subsidiary, expanding Gyre into U.S.-China integrated biopharmaceutical operations
- Former Cullgen CEO Ying Luo became Gyre CEO, President and board member; Ping Zhang remains chairman
- Combined company retains Nasdaq Capital Market listing under ticker GYRE
- Asset base now combines China commercial revenue from ETUARY® with F351, fibrosis programs and Cullgen’s degrader pipeline
Other items in this filing:
- Item 3.02: Unregistered Sales of Equity Securities
- Item 3.03: Material Modification to Rights of Security Holders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.